- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05240885
Metabole en functionele gevolgen van veroudering in gezondheid en ziekte
Considerable heterogeneity in the aging population has been observed. The exceptional longevity of individuals reaching 100 years old, so-called centenarians may be an example of life-long healthy aging, or added years may be spent in poor health with decreased physical and cognitive functioning. Current knowledge of the aging experience and the trajectories of physical and cognitive decline across various age groups are not well-understood, yet crucial to prevent spending added years in disease. Hence, the study objective is to develop the metabolic profile associated with aging-related disorders measured as the incidence of impaired functional capacity, cognitive function, and/or well-being.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Our lab developed a pulse method combining multiple stable tracers to study multiple metabolic pathways in the same individual simultaneously. By measuring whole-body metabolism in a large group of older adults, we may be able to unravel age-related deterioration in protein turnover (synthesis and breakdown) that contributes to impaired functional capacity. Metabolic profiles could explain differences in pathways in the aging process with a special interest in the metabolism of amino acids as they have been associated with aging-related disorders. Studies on the effect of aging on metabolism might serve as potential therapeutic targets.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Laura Ruebush, PhD
- Telefoonnummer: 979-422-1789
- E-mail: le.ruebush@ctral.org
Studie Contact Back-up
- Naam: Marielle Engelen, PhD
- Telefoonnummer: 979-422-1789
- E-mail: mpkj.engelen@ctral.org
Studie Locaties
-
-
Texas
-
College Station, Texas, Verenigde Staten, 77845
- Werving
- Human Clinical Research Building
-
Contact:
- Laura Ruebush, PhD
- E-mail: le.ruebush@ctral.org
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
We will screen 400 subjects (to complete n=320). This number includes screen failures and drop-outs. We expect some dropout between screening and enrollment. Subjects who drop out prior to the successful completion of the study will be replaced. Data will be used up to the point of withdrawal. Age range: 50 years or older, inclusive; Ethnicity: all races and ethnicities.
Beschrijving
Inclusion Criteria:
- Stable body-weight (± 5%) for the past 3 months
- Subject is judged to be in satisfactory health based on medical history, physical examination, and laboratory screening evaluations.
- Ability to walk, sit down and stand up independently or with walking mobility aids
- Ability to lie in a supine or elevated position for up to 3 hours
- Discharged within 30 days after a hospital admittance for >48-hours (recently hospitalized group only)
- Diagnosis of heart failure (stages 2-4 heart failure based on the New York Heart Association Functional Class; heart failure group only)
- Willingness and ability to comply with the protocol
Exclusion Criteria:
- Insulin dependent diabetes mellitus
- Established diagnosis of malignancy
- History of untreated metabolic diseases including hepatic or renal disorder
- Presence of acute illness or metabolically unstable chronic illness
- Presence of fever within the last 3 days
- Use of short course of oral corticosteroids within 4 weeks preceding study day
- Failure to give informed consent or Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements
- (Possible) pregnancy
- Already enrolled in another clinical trial and that clinical trial interferes with participating in this study
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Controls
Study subjects that are eligible based on inclusion/exclusion criteria Screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Study day(s): may include combinations of stable tracer infusions and with blood draws, cognitive and muscle performance testing |
Multiple stable-labeled tracers of amino acids, ketoacids, glycerol, short-chain fatty acids
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Age-related changes in whole-body protein and amino acid metabolism
Tijdsspanne: 2 hours
|
Whole-body production rate measured after stable tracer administration |
2 hours
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Age-related changes in whole-body glucose metabolism
Tijdsspanne: 2 hours
|
Whole-body production rate measured after stable tracer administration |
2 hours
|
|
Age-related changes in whole-body fat metabolism
Tijdsspanne: 2 hours
|
Whole-body production rate measured after stable tracer administration |
2 hours
|
|
Age-related changes in depression as measured by the Hospital Anxiety and Depression Scale (HADS) and Geriatric Depression Scale (if applicable)
Tijdsspanne: baseline visit
|
Self-reported depression measured by a validated questionnaire related to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 (no symptoms) and 21 (severe symptoms). A higher score indicates a worse outcome (greater self-reported depression symptoms). |
baseline visit
|
|
Age-related changes in anxiety as measured by the Hospital Anxiety and Depression Scale (HADS)
Tijdsspanne: baseline visit
|
Anxiety measured by a validated questionnaire related to anxiety-related symptoms. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 (no symptoms) and 21 (severe symptoms) related to anxiety. A higher score indicates a worse outcome (greater self-reported anxiety symptoms). |
baseline visit
|
|
Age-related changes in mood as measured by the Profile of Mood State (POMS)
Tijdsspanne: baseline visit
|
A psychological distress scale to measure the mood disturbance in 6 domains - fatigue-inertia, vigor-activity, tension-anxiety, depression-dejection, anger-hostility, and confusion-bewilderment in the past week. Each item on the questionnaire is awarded a score from 0 ("not at all") to 4 ("extremely"), except "Relaxed" and "Efficient" scored 4 ("not at all") and 0 ("extremely"), based on the intensity of the assessed feeling in the past week. |
baseline visit
|
|
Age-related changes in health status
Tijdsspanne: baseline visit
|
Health status assessed by Health-Related Quality of Life Scale (HR-QoL) |
baseline visit
|
|
Age-related changes in physical activity
Tijdsspanne: baseline visit
|
Physical activity assessed by Physical Activity Scale for the Elderly (PASE) |
baseline visit
|
|
Age-related changes in sleep quality
Tijdsspanne: baseline visit
|
Sleep quality assessed by Pittsburgh Sleep Quality Index |
baseline visit
|
|
Age-related changes in nutritional status
Tijdsspanne: baseline visit
|
Nutritional status assessed by Mini-Nutritional Assessment |
baseline visit
|
|
Age-related changes in attention and executive functions as measured by Trail Making Test (TMT)
Tijdsspanne: baseline visit
|
In Part A, the examinee is instructed to connect a set of 25 circles with numbers as quickly as possible while maintaining accuracy. In Part B, the examinee is instructed to connect a set of 25 circles, alternating between numbers and letters, as quickly as possible while maintaining accuracy. Measures attentional resources and is a measure of the frontal lobe "executive" functions of visual search, set-switching and mental flexibility. The total time in seconds was reported for each measure. |
baseline visit
|
|
Age-related changes in overall cognitive abilities as measured by Montreal Cognitive Assessment (MoCA)
Tijdsspanne: baseline visit
|
MoCa assesses several cognitive domains and is used for the screening of mild cognitive impairment. Total scores range from 0-30 with lower scores indicating decreased functioning. |
baseline visit
|
|
Age-related changes in exercise capacity
Tijdsspanne: baseline visit
|
Functional exercise capacity assessed by 6-minute walk test |
baseline visit
|
|
Age-related changes in physical weakness (frailty)
Tijdsspanne: baseline visit
|
Physical weakness assessed by Short Physical Performance Battery |
baseline visit
|
|
Age-related changes in skeletal muscle strength of the upper extremity
Tijdsspanne: baseline visit
|
Skeletal muscle strength measured by handgrip test |
baseline visit
|
|
Age-related changes in skeletal muscle strength of the lower extremity
Tijdsspanne: baseline visit
|
Skeletal muscle strength measured by one-leg test |
baseline visit
|
|
Age-related changes in respiratory muscle strength
Tijdsspanne: baseline visit
|
Respiratory muscle strength measured by a hand-held mouth pressure device (Micro RPM) |
baseline visit
|
|
Age-related changes in balance
Tijdsspanne: baseline visit
|
Skeletal muscle strength measured by Berg Balance Scale and balance platform |
baseline visit
|
|
Age-related changes in gut microbiota
Tijdsspanne: baseline visit
|
The amount and types of microbiota assessed in collected stool sample |
baseline visit
|
|
Age-related changes in gut function
Tijdsspanne: baseline visit
|
Gut function assessed by Gastrointestinal Symptom Rating Scale, a 15-item instrument designed to assess the symptoms associated with common gastrointestinal disorders. A higher score indicates worse outcomes (more discomfort). |
baseline visit
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Age-related changes in hand dexterity
Tijdsspanne: baseline visit
|
Hand dexterity assessed by the Nine-Hole Peg Test (9-HPT), a standardized, quantitative assessment in which the subject is asked to take pegs from a container, one by one, and place them into the holes on the board. Time upon completion will be recorded using both left and right hand, separately. |
baseline visit
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2021-1413
- 82-Aging (Andere identificatie: CTRAL)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Data may be shared upon request for up to 6 years beyond completion of the trial based on methods/proposal approved by both parties' institutional review committees. Individual participant data that underlie the results of the trial may be shared after de-identification (text, tables, figures, and appendices). Additional documents available per request include: study protocol, statistical analysis plan, and informed consent. Requests should be directed to Dr. Marielle Engelen (mpkj.engelen@ctral.org).
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .